(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 October 2025 (02.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/202510 A1

(51) International Patent Classification:
C07H 17/08 (2006.01) *A61K 31/7008* (2006.01)
A61P 11/06 (2006.01)

(21) International Application Number:
PCT/EP2025/058658

(22) International Filing Date:
28 March 2025 (28.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2404587.4 28 March 2024 (28.03.2024) GB

(71) Applicant: **EPIENDO PHARMACEUTICALS EHF** [IS/IS]; Bjargargata 1, 102 Reykjavik (IS).

(72) Inventors: **TEODOROVIC, Peter**; c/o EpiEndo Pharmaceuticals EHF, Bjargargata 1, 102 Reykjavik (IS). **HORKKA, Kaisa**; c/o EpiEndo Pharmaceutical EHF, Bjargargata1, 102 Reykjavik (IS).


(74) Agent: **ABEL & IMRAY LLP**; Westpoint Building, James Street West, Bath, Bath and North East, Somerset BA1 2DA (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) Title: CRYSTALLINE SALT FORMS OF AN AZITHROMYCIN BENZOATE DERIVATIVE



(I)

(57) **Abstract:** The present invention relates to crystalline forms of azithromycin derivatives, and the pharmaceutical formulations and therapeutic uses thereof, specifically salts, for example, crystalline forms, of the macrolide, (2S,3R,4S,6R)-4-(dimethylamino)-2-[[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-6-methyl-tetrahydropyran-3-yl]benzoate), in particular, the tartrate, oxalate and naphthalene di-sulphonate salts.

WO 2025/202510 A1